UTHR United Therapeutics Corporation
Nasdaq · Health Care · Pharmaceutical Preparations · Market cap $25.2B · $541.70 on 2026-10-02
Above StickerTier ADetailed (TTM)
Price moves
1 week14%
1 month11%
3 months-3%
6 months-4%
YTD12%
1 year20%
Off 52w high-11%
52w range$409–$609
Price history
Show year-end values
| Year | Price |
|---|---|
| 2016 | $143.43 |
| 2017 | $147.95 |
| 2018 | $108.90 |
| 2019 | $88.08 |
| 2020 | $151.79 |
| 2021 | $216.08 |
| 2022 | $278.09 |
| 2023 | $219.89 |
| 2024 | $352.84 |
| 2025 | $487.25 |
| 2026-10-02 (latest) | $541.70 |
Buy (MOS)
$177
$177
Ten Cap
$235
$235
Payback Time
$350
$350
Sticker
$354
$354
Price
$542
$542
Valuation
| Buy (MOS) 50% of Sticker | $177.07 | -67% |
|---|---|---|
| Ten Cap 10× owner earnings | $235.05 | -57% |
| Payback Time 8-year FCF payback | $350.05 | -35% |
| Sticker Rule #1 intrinsic value | $354.13 | -35% |
| Windage growth g | 13.7% | |
| Future P/E (min 2g, 10y median) | 14.2× | |
| P/E · 10y median | 19.4× | 14.2× |
| EPS TTM 2026-06-30 | $27.91 | |
| FCF yield | 4.3% | |
| Dividend (TTM) · yield | – | – |
| Total return per year, dividends reinvested · 5y · 10y | 23.6% | 15.9% |
| Revenue · net income last FY | $3.2B | $1.3B |
Big Five 13/15 tests ≥10%
| 10y | 5y | 1y | |
|---|---|---|---|
| ROIC | 17% | 15% | 16% |
| Sales growth | 8% | 17% | 11% |
| EPS growth | 8% | 19% | 13% |
| BVPS growth | 17% | 14% | 12% |
| OCF growth | 15% | 16% | 18% |
| Debt payoff (yrs of FCF) | 0.0 |
Events
8-K: 2026-09-08: 1.01 Material agreement; 7.01 Reg FD disclosure; next report ~2026-11-04
Next report ≈ 2026-11-04 · SEC filings ·Yahoo Finance